Analysts Issue Forecasts for ZVRA FY2026 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share estimates for Zevra Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings of $0.98 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $25.00 price target on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.15. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $20.40 million for the quarter, compared to analysts' expectations of $16.96 million. During the same period last year, the firm earned ($0.40) earnings per share.

ZVRA has been the topic of several other reports. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen raised Zevra Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Zevra Therapeutics in a report on Thursday, March 13th. Canaccord Genuity Group upped their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. Finally, Guggenheim boosted their price objective on Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, March 13th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $22.29.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA traded down $0.01 during trading hours on Wednesday, reaching $9.37. 480,071 shares of the company's stock were exchanged, compared to its average volume of 664,348. The company has a 50-day moving average of $7.92 and a 200 day moving average of $8.08. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The firm has a market capitalization of $512.35 million, a price-to-earnings ratio of -4.76 and a beta of 2.01. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.76.

Insider Transactions at Zevra Therapeutics

In other news, Director John B. Bode acquired 10,000 shares of the firm's stock in a transaction on Wednesday, March 19th. The shares were purchased at an average cost of $7.96 per share, with a total value of $79,600.00. Following the acquisition, the director now directly owns 40,000 shares in the company, valued at $318,400. This represents a 33.33% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new stake in shares of Zevra Therapeutics during the 4th quarter valued at about $53,000. GAMMA Investing LLC grew its position in Zevra Therapeutics by 20,564.1% in the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock worth $60,000 after purchasing an additional 8,020 shares in the last quarter. Strs Ohio bought a new stake in Zevra Therapeutics during the first quarter worth $125,000. Squarepoint Ops LLC raised its holdings in shares of Zevra Therapeutics by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock worth $138,000 after purchasing an additional 4,384 shares during the period. Finally, ProShare Advisors LLC bought a new position in shares of Zevra Therapeutics during the 4th quarter worth $145,000. Institutional investors and hedge funds own 35.03% of the company's stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.